- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00305591
Brain Imaging in Patients With Chronic Liver Disease and Functional Impairment.
Functional Magnetic Resonance Imaging and Spectroscopy of the Brain in Patients With Chronic Hepatic Encephalopathy
Hepatic encephalopathy (HE) is a frequent complication of chronic liver disease (cirrhosis) and involves a wide spectrum of problems from mild impairment of reaction times in driving and operating machinery through to disturbances in mood, behaviour and conscious levels.
Magnetic resonance imaging (MRI) is a method of obtaining pictures of the inside of the body. Patients with liver disease have previously been studied with MRI which has highlighted changes in the brain. This research aims to highlight some of the differences in the way that the brain functions in patients with liver disease. Using our new, more powerful MRI scanner, with more sophisticated techniques we hope that the novel combination of MRI techniques can objectively detect the presence of , and monitor HE.
Study hypothesis: Hepatic encephalopathy (HE) is a reversible, metabolic disturbance of the brain, associated with low grade brain swelling and disturbances of the chemical balance within the brain, resulting in functional impairment, the presence of which MR imaging can detect with sufficient sensitivity to monitor the changes that may occur over time in response to treatment.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Hepatic encephalopathy (HE) is a common neuropsychiatric abnormality, complicating the course of liver disease patients. In the UK, cirrhosis accounts for 4000 deaths per year, and 500,000 people are thought to be infected with chronic hepatitis C, of which up to 20% will develop cirrhosis over 20 years. The condition has been difficult to monitor objectively.
Despite the fact that the syndrome was probably first recognised two thousand years ago, the exact pathogenesis still remains unclear. It is thought to represent a reversible disturbance in brain chemistry and consequent brain swelling, in response to blood containing unfiltered gut-derived toxins entering the cerebral circulation. There is no recognised 'gold standard' test to diagnose and monitor this important, disabling condition. I have developed a novel combination of magnetic resonance imaging (MRI) sequences at 3 Tesla to study the effects of hepatic encephalopathy on the brain in patients with cirrhosis.
We propose to investigate alterations in brain size, function and chemistry before, and then at intervals after 4 weeks anti-encephalopathy treatment with L-ornithine L-aspartate. This will enable the assessment of both the baseline brain alterations of the cohort and the brain's response to therapy and correlation with their clinical response. As such this longitudinal study would allow us to define the sensitivity of the MR techniques.
Each of 50 patients will have blood tests, a 1 hour MRI brain scan and psychometric testing. The psychometric testing will be performed with both a computer-based battery and conventional paer-based tests. They will then be given L-ornithine L-aspartate (LOLA) to take orally for 4 weeks and have repeat blood tests, MRI and psychometric tests.
We will then determine if there is a correlation between the MR data and the results of the psychometric testing.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
London
-
Hammersmith, London, United Kingdom, W12 0HS
- Imperial College London
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 18-65
- Biopsy-proven cirrhosis
- Clinically stable
- Able to give informed consent
- Fluent English (required for psychometric testing)
Exclusion Criteria:
- Ferro-magnetic implants
- Claustrophobia
- Weight >120kg
- Significant renal impairment (Creatinine >150 micromol/L)
- Poorly controlled Diabetes (particularly type I with microvascular complications)
- Alcohol: if alcoholic liver disease is the aetiology of their liver disease they should be abstinent. Otherwise less than 20g per day.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
All enrolled patients will be given 4 weeks of treatment. Both MRI and functional changes will be observed.
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Simon D Taylor-Robinson, MBBS, FRCP, Imperial College London & St Mary's Hospital
Study record dates
Study Major Dates
Study Start
Primary Completion
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Liver Failure
- Hepatic Insufficiency
- Pathologic Processes
- Metabolic Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Liver Diseases
- Brain Diseases, Metabolic
- Fibrosis
- Hepatic Encephalopathy
- Brain Diseases
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Excitatory Amino Acid Agents
- Excitatory Amino Acid Agonists
- N-Methylaspartate
Other Study ID Numbers
- 04/Q0406/161
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatic Encephalopathy
-
Jinnah Postgraduate Medical CentreNot yet recruitingHepatic Encephalopathy Stage 2 | Hepatic Encephalopathy Stage 3 | Hepatic Encephalopathy Stage 4Pakistan
-
Sherief Abd-ElsalamTanta UniversityUnknownEncephalopathy, HepaticEgypt
-
Institute of Liver and Biliary Sciences, IndiaWithdrawnRefractory Hepatic EncephalopathyIndia
-
Tel-Aviv Sourasky Medical CenterUnknown
-
Hunter Holmes Mcguire Veteran Affairs Medical CenterInstituto Grifols, S.A.; McGuire Research InstituteCompletedHepatic Encephalopathy | Cirrhosis | Minimal Hepatic Encephalopathy | Covert Hepatic EncephalopathyUnited States
-
Aga Khan UniversityUnknownEncephalopathy, Hepatic | Hepatocerebral Encephalopathy | Portal-Systemic Encephalopathy | Encephalopathy, HepatocerebralPakistan
-
Consorci Sanitari de l'Alt Penedès i GarrafWithdrawn
-
Bausch Health Americas, Inc.CompletedOvert Hepatic EncephalopathyUnited States
-
Shanghai Changzheng HospitalCompletedCovert Hepatic EncephalopathyChina
-
Fondazione Policlinico Universitario Agostino Gemelli...CompletedMinimal Hepatic EncephalopathyItaly
Clinical Trials on l-ornithine l-aspartate
-
Hospital de Clinicas de Porto AlegreUnknownHepatic EncephalopathyBrazil
-
Air Force Military Medical University, ChinaCompletedDecompensated Cirrhosis | Portal Hypertension | Bleeding Varices | Refractory AscitesChina
-
All India Institute of Medical Sciences, New DelhiUnknownAcute Liver FailureIndia
-
Aga Khan UniversityCompletedHepatic EncephalopathyPakistan
-
Institute of Liver and Biliary Sciences, IndiaNot yet recruiting
-
Medical University of GrazCBmed Ges.m.b.H.Recruiting
-
Dayanand Medical College and HospitalCompletedHepatic Encephalopathy | Cirrhosis of LiverIndia
-
Centro Regional para el Estudio de las Enfermedades...MERZ PHARMACompleted
-
Ukrainian Medical Stomatological AcademyCompleted
-
Mahidol UniversityCompletedHepatic EncephalopathyThailand